Survival and complication rates in patients with thalassemia major in Taiwan

Pediatric Blood and Cancer

Volumn 64, Issue 1, 2017, Pages 135-138

  Wu, Han Ping ^a,b   Lin, Cheng Li ^c,d   Chang, Yin Chen ^e   Wu, Kang Hsi ^e   Lei, Rouh Lih ^f   Peng, Ching Tien ^e,g   Weng, Tefu ^e   Tai, Yu Man ^e   Chao, Yu Hua ^h,i  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f HUNGKUANG UNIVERSITY   (Taiwan)

^g ASIA UNIVERSITY   (Taiwan)

^h CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

complication; national health insurance; survival; Taiwan; thalassemia major

Indexed keywords

DEFERASIROX; DEFERIPRONE;

ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; ENDOCRINE DISEASE; ERYTHROCYTE TRANSFUSION; FEMALE; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; HYPOGONADISM; HYPOPARATHYROIDISM; HYPOTHYROIDISM; INFANT; IRON CHELATION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; OSTEOPOROSIS; PRIORITY JOURNAL; SURVIVAL; TAIWAN; THALASSEMIA MAJOR; BETA-THALASSEMIA; CHELATION THERAPY; COMPLICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LONGITUDINAL STUDY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEWBORN; PRESCHOOL CHILD; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMBINED MODALITY THERAPY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TAIWAN; YOUNG ADULT;

EID: 84992066398     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.26181     Document Type: Article

References (26)

1. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010;115:4331–4336.
2. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005;353:1135–1146.
3. Marsella M, Borgna-Pignatti C. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease. Hematol Oncol Clin North Am. 2014;28:703–727.
4. Borgna-Pignatti C, Marsella M. Iron chelation in thalassemia major. Clin Therapeut. 2015;37:2866–2877.
5. Smith RS. Iron excretion in thalassaemia major after administration of chelating agents. Br Med J. 1962;2:1577–1580.
6. Peng CT, Wu KH, Wu SF, et al. Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan. Hemoglobin. 2006;30:125–130.
7. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010;95:557–566.
8. Chao YH, Wu KH, Lin CY, et al. Audiologic and vestibular assessment in patients with beta-thalassemia major receiving long-term transfusion therapy. Pediatr Blood Cancer. 2013;60:1963–1966.
9. Chen YC, Wu JC, Haschler I, Majeed A, Chen TJ, Wetter T. Academic impact of a public electronic health database: bibliometric analysis of studies using the general practice research database. PLoS ONE. 2011;6:e21404.
10. Peng CT, Chang JS, Wang LY, et al. Update on thalassemia treatment in Taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects. Hemoglobin. 2009;33:304–311.
11. Maggio A, Vitrano A, Capra M, et al. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis. 2009;42:247–251.
12. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187–1193.
13. Yin XL, Wu ZK, He YY, Zhou TH, Zhou YL, Zhang XH. Treatment and complications of thalassemia major in Guangxi, Southern China. Pediatr Blood Cancer. 2011;57:1174–1178.
14. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 1998;850:227–231.
15. Vichinsky E, Neumayr L, Trimble S, et al. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). Transfusion. 2014;54:972–981.
16. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR, Thalassemia Clinical Research N. Complications of beta-thalassemia major in North America. Blood. 2004;104:34–39.
17. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355:2051–2052.
18. Chern JPS, Su S, Lin KH, et al. Survival, mortality, and complications in patients with beta-thalassemia major in northern Taiwan. Pediatr Blood Cancer. 2007;48:550–554.
19. Jaing TH, Hung IJ, Yang CP, et al. Unrelated cord blood transplantation for thalassaemia: a single-institution experience of 35 patients. Bone Marrow Transplant. 2012;47:33–39.
20. Lin KH, Lin KS. Allogeneic bone marrow transplantation for thalassemia in Taiwan: factors associated with graft failure. Am J Pediatr Hematol Oncol. 1989;11:417–423.
21. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322:417–421.
22. Huang YC, Chang JS, Wu KH, Peng CT. Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. Hemoglobin. 2006;30:229–238.
23. Peng CT, Tsai CH, Wu KH. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience. Hemoglobin. 2008;32:49–62.
24. Wang CH, Wu KH, Tsai FJ, Peng CT, Tsai CH. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients. Hemoglobin. 2006;30:257–262.
25. Mazza P, Giua R, De Marco S, et al. Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver. Haematologica. 1995;80:398–404.
26. Porter JB. Monitoring and treatment of iron overload: state of the art and new approaches. Semin Hematol. 2005;42:S14–S18.